Clinical and immunohistochemical study of eight cases with thymic carcinoma

Tomita, Masaki; Matsuzaki, Yasunori; Edagawa, Masao; Maeda, Masayuki; Shimizu, Tetsuya; Hara, Masaki; Onitsuka, Toshio

doi:10.1186/1471-2482-2-3

Cited by 21 publications

(19 citation statements)

References 22 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also found that thymic carcinomas have more aggressive angiogenic function than thymomas. The results of these observation in the present study were consistent with the previous reports [22,23].…”

Section: Discussionsupporting

confidence: 95%

L‐type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas

Kaira

Oriuchi

Imai

et al. 2009

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 95%

L‐type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas

Kaira

Oriuchi

Imai

et al. 2009

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…17,22,23,34,37,41,[43][44][45][46][47][48] This finding is in keeping with the observation in other thymic neoplasms that proliferative activity is linked with overexpression of p53 protein, particularly in more aggressive histologic grade tumors. 23,25 However, we found that low-grade thymic neuroendocrine tumors, which morphologically resembled typical carcinoid tumors, did not have the low labeling indices that we had previously reported in their low-grade pulmonary counterparts. 48 The high proliferation rate that frequently occurs in thymic neuroendocrine tumors could be a key factor in explaining its aggressive biological behavior.…”

Section: Discussioncontrasting

confidence: 43%

“…[17][18][19][20][21][22][23] Thymic carcinomas, in contrast, generally have shown increased mutant p53 expression, higher proliferation rates, and a tendency to express Bcl-2. 16,[19][20][21][22][23][24][25] Although many of the previous studies have focused on non-neuroendocrine thymic neoplasms, there has been very little attention regarding these factors in thymic neuroendocrine tumors, and there has not been a systematic study of these markers with standardized immunohistochemical scoring and rigorous statistical analysis for a large series of cases (Table 3). 14,[26][27][28][29] This prompted us to focus on some of these factors, namely, p53 expression, cellular proliferation, the antiapoptosis markers Bcl-2 and Bcl-x, and the proapoptosis marker Bax.…”

Section: Discussionmentioning

confidence: 99%

p53, cellular proliferation, and apoptosis-related factors in thymic neuroendocrine tumors

et al. 2004

View full text Add to dashboard Cite

Thymic neuroendocrine tumors are biologically aggressive neoplasms with extensive local invasion and high mortality. Although various markers of cellular proliferation and apoptosis have correlated with degrees of tumor differentiation in pulmonary neuroendocrine neoplasms, they have not been systematically studied in thymic neuroendocrine tumors. We immunostained 21 cases of thymic neuroendocrine tumors for p53, MIB-1, and the apoptosis-related markers Bcl-2, Bcl-x, and Bax. By histological classification the cases were low-grade (nine cases), intermediate-grade (eight cases), and high-grade (four cases) thymic neuroendocrine tumors. p53 was expressed in five cases: 1/9 low grade, 3/8 intermediate grade, and 2/4 high grade. The mean cellular proliferation (MIB-1) was 7.1% (range 2-12%) in low-grade thymic neuroendocrine tumors, 6.1% (range 2-15%) in intermediate-grade thymic neuroendocrine tumors, and 34.2% (range 2-80%) in high-grade thymic neuroendocrine tumors. Bcl-2 was expressed in 16 cases: 7/9 low grade, 5/8 intermediate grade, and 4/4 high grade. Bcl-x was expressed in 16 cases: 7/9 low grade, 6/8 intermediate grade, and 3/4 high grade. Bax was expressed in 13 cases: 5/9 low grade, 4/8 intermediate grade, and 4/4 high grade. The presence of mutant p53 in the tumor was associated with a statistically significant decreased mean survival (Po0.05). In contrast, either by positive or negative staining or by the score technique (staining intensity Â percentage of cells staining), the presence of Bcl-x was associated with an increased mean survival (Po0.05). Finally, a Bcl-x : Bax ratio Z1 was also associated with an increased mean survival, as compared to a Bcl-x : Bax ratio Z1 (Po0.05). Our study shows that p53 expression and certain apoptosis markers correlate with survival. The expression of these markers may account for differences in biological behavior.

show abstract

“…Nine studies reported that the staging wasn't a relevant prognostic factor [6,9,19,20,30,46,57,71,74]. These studies reported that the vascular invasion was a bad prognosis factor and that it needs to be integrated in the staging system [46,57,71]. The surgical resecability of thymic carcinomas has been reported in many studies [4][5][6]8 [22].…”

Section: Discussionmentioning

confidence: 99%

“…The expression of Kit was also used as a diagnostic tool of these tumors [39,93] [8,31,67]. Nine studies reported that the staging wasn't a relevant prognostic factor [6,9,19,20,30,46,57,71,74]. These studies reported that the vascular invasion was a bad prognosis factor and that it needs to be integrated in the staging system [46,57,71].…”

Section: Discussionmentioning

confidence: 99%

Review of the literature about Thymic Carcinomas

Mlika¹,

Mezni²

2017

Arch Pulmonol Respir Care

View full text Add to dashboard Cite

Background: Thymic carcinomas (TC) are rare tumors with challenging diagnosis and management. We aimed to describe the clinical and microscopic characteristics of TC through a literature review.Results: 82 articles and abstracts were retained about 2913 TC. Our study contained 1760 men and 1153 women with a mean age of 55.32 years. The delay of diagnosis was specifi ed in 10 cases and varied between 8 months and 2 years. Symptoms consisted mainly in chest pain and dyspnea. The Computed Tomography-scan (CT-scan) fi ndings were specifi ed in 63 cases. Microscopic fi ndings were noticed in 1766 cases. They consisted mainly in squamous cell carcinoma in 1297 cases and undifferentiated carcinoma in 239 cases. The patients presented stage 1 tumors in 165 cases, stage II in 362 cases, stage III in 1011 cases and stage IV in 1166 cases. The treatment modalities were noticed in 2803 cases. There was no consensus of the regimen of chemotherapy or the place of the radiation therapy but all studies highlighted the key role of the complete surgical resection when possible. Conclusion:Our results highlight the lack of consensual management of TC. The chemotherapy regimen, the second-line chemotherapy and the indications of radiation therapy seem non-consensual and need further studies. Many interrogations remain concerning the management of these tumors according to their histologic grade. The real place of targeted therapy remains to assess and the rare opinions published are based on rare and non-representative cases.

show abstract

Clinical and immunohistochemical study of eight cases with thymic carcinoma

Cited by 21 publications

References 22 publications

L‐type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas

L‐type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas

p53, cellular proliferation, and apoptosis-related factors in thymic neuroendocrine tumors

Review of the literature about Thymic Carcinomas

Contact Info

Product

Resources

About